Thu, Sep 18, 2014, 6:44 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

ubenreubed 8 posts  |  Last Activity: Aug 29, 2014 2:08 PM Member since: Jul 12, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ubenreubed by ubenreubed Aug 29, 2014 2:08 PM Flag

    I'm surprised nobody mentioned the one year anniversary of our infamous "untitled letter"....amazing how fast a year goes :)

  • ubenreubed by ubenreubed Jul 30, 2014 7:18 AM Flag

    Suraj Kalia - Northland Securities
    So Bill, Pete or Mike, I guess I just have one question, I would like to follow-up on Bill’s question earlier, to the extent that you can – can you walk us through the comp structure of the 10 year sales reps. And I’m curious to know how many of these new reps you all have hired are ex-shire reps and finally, SG&A was round if my math serves me right around 79% of sales last year. And Pete I think so you all gave pretty good color in terms of, you’ll expect synergies to come in, I’m curious how you’ll see synergies come in given everything going on in the industry. I know a long winded question, but hopefully you get the just of it? Thanks for taking my question.
    Pete Petit
    I would first of all, I got little uncomfortable with the fact that we’re given a lot of specifics here on our conversation and how we’re doing certain things and I’m not going to do that anymore, okay. I’ll just [indiscernible] Bill and Mike that’s our business, I know you analyst want to drop your models, but really how we hire people and how we compensate them and when we do this and when we do that, I think we’ll keep that to our sales in the future.

    Now you are asking for a lot of specifics and I’m going to throw it back to you and say give me, I’m not going – we are not going to see any more questions about how we compensate sales organization, I think we’ve done enough of that. So come back to me with another question.

  • Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that AMNIOEXCEL®, its novel human amniotic membrane allograft, has been approved by the Veterans Administration (VA) for inclusion in its Federal Supply Schedule V797P-2000D. The announcement marks Derma Sciences’ official launch with its expanded U.S. sales force to sell AMNIOEXCEL into VA and military medical centers, outpatient clinics and community living centers across the U.S. AMNIOEXCEL has been rapidly adopted by clinicians in several test facilities for use in patient care and a 10-patient case series has been submitted for publication in a peer-reviewed journal. In addition, Derma Sciences expects to begin a randomized clinical trial with AMNIOEXCEL in August to further support marketing into additional channels.
    “Inclusion in the Federal Supply Schedule is an important milestone for our newly acquired AMNIO product line as we continue to position Derma Sciences as a leading wound care company specializing in tissue regeneration,” said Edward J. Quilty, chief executive officer of Derma Sciences. “Amniotic tissue technology facilitates excellent clinical outcomes with difficult, non-healing wounds and we are delighted that active military personnel and veterans will benefit from access to another of our advanced products. Based on the early clinical evaluations of AMNIOEXCEL in certain VA hospitals, we are confident that our product will offer clinicians a best-in-class product with a compelling combination of clinical efficacy and ease-of-use.”
    “In addition, AMNIOEXCEL meets Centers for Medicare & Medicaid Services (CMS) guidelines for placement into the high cost tier skin substitutes,” Mr. Quilty continued. “This product is priced to be in line with the new CMS bundled payment initiative for skin substitute guidelines that became effective January 1, 2014, thus ensuring cost savings. Given the positive clinical results achieved following thorough product evaluations on patients, prosthetics purchasing departments in many VA facilities have acknowledged that the resultant savings from using AMNIOEXCEL will allow them to help more veterans and active military personnel with other important healthcare needs.”
    Barry J. Wolfenson, group president of advanced wound care and drug development at Derma Sciences, added, “With this approval, we can now implement the next part of our business plan by achieving more widespread utilization of AMNIOEXCEL in this $500 million market. This will help us to develop an even broader base of key opinion leaders, which will be critical as we work diligently to secure coverage from the Medicare Administrative Contractors. We look forward to announcing our progress in this area in the coming months

  • Reply to

    Seeking Alpha Pro has an OSIR article

    by ubenreubed Jul 10, 2014 12:18 PM
    ubenreubed ubenreubed Jul 10, 2014 12:20 PM Flag

  • basically says the company's survival is in doubt after losing pass-through-status in 2015. We believe Grafix will be a huge commercial failure and Osiris's future is doomed.....

  • Reply to


    by earth457 Jun 27, 2014 2:33 PM
    ubenreubed ubenreubed Jun 30, 2014 10:24 AM Flag

    The Russell Indices had a rebalance on Friday..

    Sentiment: Strong Buy

  • ubenreubed by ubenreubed Jun 19, 2014 12:14 PM Flag

    Does anyone know how long each of those takes? or is it whenever the FDA gets around to it? just wondering if that's why the price action is muted in light of the news....

    Sentiment: Strong Buy

  • Reply to

    Osiris news

    by cimcbride Jun 19, 2014 9:55 AM
    ubenreubed ubenreubed Jun 19, 2014 10:07 AM Flag

    Grafix® Manuscript from Osiris’ Multi-center, Randomized, Controlled Clinical Trial Accepted in Peer-Reviewed Journal

    June 19, 2014 12:00:00 UTC

    The trial demonstrated the overwhelming efficacy of Grafix compared to conventional wound therapy in the closure of Diabetic Foot Ulcers

    Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to control in patients with chronic diabetic foot ulcers (DFUs) has been accepted for publication in the International Wound Journal. The peer-reviewed journal will report findings from Osiris’ trial, Protocol 302, which demonstrated the overwhelming efficacy of Grafix compared to control in the closure of DFUs over 12 weeks (62% vs. 21.3%, p=0.0001, n=97). Entitled “The Efficacy and Safety of Grafix for the Treatment of Chronic Diabetic Foot Ulcers: Results of a Multicenter, Controlled, Randomized, Blinded, Clinical Trial”, the publication will also highlight the trial’s secondary endpoints – all of which showed statistically significant improvements for patients treated with Grafix compared to control. Grafix was not only favored in time to wound closure (42 days vs. 70 days, p=0.019), number of treatment applications (6 vs. 12, p=0.0001) and probability of wound closure by 12 weeks (67.1% vs. 27.1%, p

7.40+0.27(+3.79%)Sep 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.